Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(9 years from now) | |
US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Prevention and treatment of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS